<!DOCTYPE html>
<html lang="zh-CN">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>vMTB Consultation Report | Unknown</title>
  <style>
    :root {
      --primary: #0d47a1;
      --secondary: #546e7a;
      --accent: #00838f;
      --warning: #f57c00;
      --danger: #c62828;
      --success: #2e7d32;
      --bg: #ffffff;
      --bg-alt: #f5f7fa;
      --text: #212121;
      --text-light: #616161;
      --border: #e0e0e0;
    }

    * { box-sizing: border-box; margin: 0; padding: 0; }

    body {
      font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", "Microsoft YaHei", sans-serif;
      background: var(--bg-alt);
      color: var(--text);
      line-height: 1.6;
      font-size: 14px;
      padding: 20px;
    }

    .container {
      max-width: 1100px;
      margin: 0 auto;
      background: var(--bg);
      box-shadow: 0 1px 3px rgba(0,0,0,0.1);
    }

    header {
      background: var(--primary);
      color: white;
      padding: 24px 32px;
      display: flex;
      justify-content: space-between;
      align-items: center;
    }

    header h1 {
      font-size: 20px;
      font-weight: 600;
      letter-spacing: 0.5px;
    }

    .header-meta {
      text-align: right;
      font-size: 12px;
      opacity: 0.9;
    }

    .section {
      padding: 24px 32px;
      border-bottom: 1px solid var(--border);
    }

    .section-title {
      font-size: 16px;
      font-weight: 600;
      color: var(--primary);
      margin-bottom: 16px;
      padding-bottom: 8px;
      border-bottom: 2px solid var(--primary);
    }

    h2 {
      color: var(--primary);
      font-size: 1.3em;
      margin-top: 24px;
      margin-bottom: 12px;
      padding-bottom: 8px;
      border-bottom: 2px solid var(--primary);
    }

    h3 {
      color: var(--secondary);
      font-size: 1.1em;
      margin-top: 16px;
      margin-bottom: 8px;
    }

    p { margin-bottom: 12px; }

    ul, ol {
      margin-left: 20px;
      margin-bottom: 12px;
    }

    li { margin-bottom: 6px; }

    /* Info Grid */
    .info-grid {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(160px, 1fr));
      gap: 16px;
    }

    .info-item {
      padding: 12px;
      background: var(--bg-alt);
      border-radius: 4px;
    }

    .info-item label {
      font-size: 11px;
      color: var(--text-light);
      text-transform: uppercase;
      letter-spacing: 0.5px;
      display: block;
      margin-bottom: 4px;
    }

    .info-item span { font-size: 14px; font-weight: 500; }

    /* Tables */
    table {
      width: 100%;
      border-collapse: collapse;
      font-size: 13px;
      margin: 16px 0;
    }

    th, td {
      padding: 10px 12px;
      text-align: left;
      border: 1px solid var(--border);
    }

    th {
      background: var(--bg-alt);
      font-weight: 600;
      color: var(--secondary);
    }

    tr:nth-child(even) { background: var(--bg-alt); }

    /* Badges */
    .badge {
      display: inline-block;
      padding: 2px 8px;
      border-radius: 3px;
      font-size: 11px;
      font-weight: 600;
    }

    .badge-success { background: #e8f5e9; color: var(--success); }
    .badge-warning { background: #fff3e0; color: var(--warning); }
    .badge-danger  { background: #ffebee; color: var(--danger); }
    .badge-info    { background: #e3f2fd; color: var(--primary); }
    .badge-secondary { background: #eceff1; color: var(--secondary); }
    .badge-primary { background: var(--primary); color: white; }

    /* Executive Summary */
    .exec-summary {
      background: var(--bg-alt);
      padding: 20px;
      border-radius: 4px;
      border-left: 4px solid var(--primary);
      margin-bottom: 20px;
    }

    .exec-summary h3 {
      font-size: 14px;
      color: var(--primary);
      margin-bottom: 12px;
    }

    .exec-summary ul { list-style: none; padding: 0; margin: 0; }

    .exec-summary li {
      padding: 6px 0;
      border-bottom: 1px solid var(--border);
    }

    .exec-summary li:last-child { border-bottom: none; }

    /* Card Grid */
    .card-grid {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
      gap: 16px;
      margin: 16px 0;
    }

    .card {
      border: 1px solid var(--border);
      border-radius: 4px;
      padding: 16px;
    }

    .card-header {
      font-weight: 600;
      color: var(--primary);
      margin-bottom: 12px;
      padding-bottom: 8px;
      border-bottom: 1px solid var(--border);
    }

    /* Treatment Timeline */
    .treatment-timeline {
      position: relative;
      padding-left: 60px;
      margin: 20px 0;
    }

    .treatment-timeline::before {
      content: '';
      position: absolute;
      left: 24px;
      top: 0;
      bottom: 0;
      width: 2px;
      background: var(--border);
    }

    .treatment-item {
      position: relative;
      margin-bottom: 16px;
      display: flex;
      align-items: flex-start;
    }

    .treatment-marker {
      position: absolute;
      left: -60px;
      width: 48px;
      height: 48px;
      background: var(--primary);
      color: white;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 600;
      font-size: 14px;
      z-index: 1;
    }

    .treatment-marker.event { background: var(--secondary); }
    .treatment-marker.adjuvant { background: #7e57c2; }
    .treatment-marker.maint { background: #26a69a; }
    .treatment-marker.pd { background: var(--danger); }
    .treatment-marker.current { background: var(--warning); color: var(--text); }
    .treatment-marker.surgery { background: var(--secondary); }
    .treatment-marker.neoadjuvant { background: var(--primary); }

    .treatment-content {
      flex: 1;
      background: var(--bg-alt);
      border-radius: 4px;
      padding: 12px 16px;
      border-left: 3px solid var(--primary);
    }

    .treatment-item.event .treatment-content { border-left-color: var(--secondary); }
    .treatment-item.adjuvant .treatment-content { border-left-color: #7e57c2; }
    .treatment-item.maint .treatment-content { border-left-color: #26a69a; }
    .treatment-item.pd .treatment-content { border-left-color: var(--danger); }
    .treatment-item.surgery .treatment-content { border-left-color: var(--secondary); }

    .treatment-header {
      display: flex;
      justify-content: space-between;
      align-items: center;
      margin-bottom: 8px;
    }

    .treatment-date { font-weight: 600; color: var(--primary); }
    .treatment-body { font-size: 14px; }

    .treatment-note {
      font-size: 12px;
      margin-top: 6px;
      padding-left: 8px;
      border-left: 2px solid var(--border);
      color: var(--text-light);
    }

    /* Key Recommendations */
    .key-rec {
      display: flex;
      align-items: flex-start;
      padding: 12px;
      background: var(--bg-alt);
      margin-bottom: 8px;
      border-radius: 4px;
    }

    .key-rec-num {
      width: 24px;
      height: 24px;
      background: var(--primary);
      color: white;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 12px;
      font-weight: 600;
      margin-right: 12px;
      flex-shrink: 0;
    }

    /* Inline Citations with Tooltip */
    .cite {
      color: var(--primary);
      cursor: pointer;
      text-decoration: none;
      font-size: 11px;
      vertical-align: super;
      font-weight: 600;
    }
    .cite:hover { text-decoration: underline; }

    .ref-tooltip {
      position: relative;
      display: inline;
    }

    .ref-tooltip .ref-text {
      visibility: hidden;
      background: #333;
      color: #fff;
      padding: 10px 14px;
      border-radius: 6px;
      position: absolute;
      z-index: 100;
      bottom: 125%;
      left: 50%;
      transform: translateX(-50%);
      width: 350px;
      font-size: 12px;
      line-height: 1.5;
      white-space: normal;
      box-shadow: 0 4px 12px rgba(0,0,0,0.3);
    }

    .ref-tooltip .ref-text::after {
      content: '';
      position: absolute;
      top: 100%;
      left: 50%;
      margin-left: -6px;
      border-width: 6px;
      border-style: solid;
      border-color: #333 transparent transparent transparent;
    }

    .ref-tooltip:hover .ref-text { visibility: visible; }

    /* Evidence Tags */
    .evidence {
      font-size: 10px;
      padding: 1px 6px;
      border-radius: 2px;
      margin-left: 6px;
    }

    .evidence-high   { background: #c8e6c9; color: var(--success); }
    .evidence-medium { background: #fff9c4; color: #f57f17; }
    .evidence-low    { background: #ffcdd2; color: var(--danger); }

    .evidence-tag {
      display: inline-block;
      padding: 2px 8px;
      border-radius: 4px;
      font-size: 11px;
      font-weight: 500;
      margin-left: 5px;
    }

    .evidence-a { background: #dcfce7; color: #166534; }
    .evidence-b { background: #dbeafe; color: #1e40af; }
    .evidence-c { background: #fef3c7; color: #92400e; }
    .evidence-d { background: #fee2e2; color: #991b1b; }

    /* Calculation Box */
    .calc-box {
      background: var(--bg-alt);
      padding: 16px;
      border-radius: 4px;
      font-family: "SF Mono", Monaco, monospace;
      font-size: 13px;
      margin: 12px 0;
    }

    .calc-box h4 {
      font-family: -apple-system, sans-serif;
      font-size: 13px;
      margin-bottom: 8px;
    }

    /* Drug Comparison Row */
    .drug-row {
      display: grid;
      grid-template-columns: 140px repeat(4, 1fr);
      gap: 1px;
      background: var(--border);
      margin-bottom: 16px;
    }

    .drug-row > div {
      background: var(--bg);
      padding: 10px;
      font-size: 13px;
    }

    .drug-row .drug-name {
      background: var(--primary);
      color: white;
      font-weight: 600;
    }

    /* Warning Box */
    .warning-box {
      background: #fef2f2;
      border-left: 4px solid var(--danger);
      padding: 15px 20px;
      margin: 20px 0;
      border-radius: 0 8px 8px 0;
    }

    .warning-box strong {
      color: var(--danger);
    }

    /* Info Box */
    .info-box {
      background: var(--bg-alt);
      border-left: 4px solid var(--primary);
      padding: 15px 20px;
      margin: 20px 0;
      border-radius: 0 8px 8px 0;
    }

    /* Utility Classes */
    .highlight { background: #fff9c4; padding: 0 2px; }
    .text-danger { color: var(--danger); }
    .text-success { color: var(--success); }
    .text-warning { color: var(--warning); }

    /* Reference Links */
    .reference {
      color: var(--primary);
      text-decoration: none;
      transition: color 0.2s;
    }

    .reference:hover {
      color: var(--accent);
      text-decoration: underline;
    }

    /* Footer */
    footer {
      padding: 16px 32px;
      background: var(--bg-alt);
      text-align: center;
      font-size: 11px;
      color: var(--text-light);
    }

    /* Print Styles */
    @media print {
      body { background: white; padding: 0; }
      .container { box-shadow: none; }
      .section { page-break-inside: avoid; }
      .ref-tooltip .ref-text { display: none; }
    }

    /* Content Area */
    .content {
      padding: 24px 32px;
    }
  </style>
</head>
<body>
  <div class="container">

    <!-- Header -->
    <header>
      <h1>虚拟分子肿瘤委员会会诊报告</h1>
      <div class="header-meta">
        <div>vMTB Consultation Report</div>
        <div>患者编号: Unknown</div>
        <div>肿瘤类型: 乙状结肠中分化腺癌</div>
        <div>报告日期: 2026-01-19 19:36:11</div>
      </div>
    </header>

    <!-- Report Content -->
    <div class="content">
      <p>这里是基于您提供的病历原文、病理报告、分子报告、临床试验报告及治疗方案汇总生成的最终 MTB 报告。</p>
<p>根据您的要求，本报告完整保留了所有治疗历史记录、临床试验推荐及关键分子细节，并针对患者严重的肾功能损伤进行了安全性调整。</p>
<hr />
<h1>分子肿瘤委员会 (MTB) 综合报告</h1>
<h2>1. 执行摘要 (Executive Summary)</h2>
<div class="exec-summary"><h3>执行摘要</h3><ul><li><strong>患者:</strong> 70岁男性，乙状结肠中分化腺癌，IV期 (ypT4aN2aM1)</li><li><strong>关键分子特征:</strong> KRAS G12C (11.5%), ATM 胚系突变, MSS, TMB-H (79 mut/Mb)</li><li><strong>当前治疗:</strong> 氟泽雷赛 + 西妥昔单抗 (2025.10起，五线治疗)</li><li><strong>核心建议:</strong> 维持当前双靶向方案，严密监测肾功能及电解质；后线首选减量TAS-102联合贝伐珠单抗。</li><li><strong>紧急程度:</strong> 常规 (密切监测肾毒性)</li></ul></div>

<p><strong>摘要</strong>:<br />
患者为晚期结直肠癌，携带少见的 <strong>KRAS G12C</strong> 突变及 <strong>ATM 胚系突变</strong>。尽管 TMB 极高 (79 mut/Mb)，但为 MSS 表型且既往免疫治疗（含疫苗联合）均告失败，提示为免疫难治性肿瘤。目前正接受 <strong>氟泽雷赛+西妥昔单抗</strong> 治疗，符合最新国际标准 <span class="evidence-tag evidence-b">Evidence B</span>。主要临床挑战在于 <strong>肾功能不全 (eGFR ~39 mL/min)</strong> 及既往 TKI 导致的急性肾损伤史。MTB 建议继续当前精准治疗，严格回避肾毒性药物，后续治疗优先考虑安全性较好的 TAS-102 联合方案或特定临床试验。</p>
<hr />
<h2>2. 患者概况 (Patient Profile)</h2>
<h3>Demographics</h3>
<ul>
<li><strong>Age</strong>: 70 岁</li>
<li><strong>Sex</strong>: 男性</li>
<li><strong>ECOG PS</strong>: 1 分 (生活自理)</li>
</ul>
<h3>Cancer Diagnosis</h3>
<ul>
<li><strong>Primary Cancer</strong>: 乙状结肠恶性肿瘤</li>
<li><strong>Histology</strong>: 中分化腺癌</li>
<li><strong>Stage</strong>: IV 期 (ypT4aN2aM1) - 术后病理分期</li>
<li><strong>Metastatic Sites</strong>: 双肺 (多发，最大 2.1cm，当前主要进展部位)；肝脏、淋巴结 (已切除)</li>
<li><strong>Date of Diagnosis</strong>: 2022年8月 (初诊)</li>
</ul>
<h3>Comorbidities</h3>
<ul>
<li><strong>Renal</strong>: <strong>慢性肾功能不全</strong> (肌酐 146 μmol/L, eGFR ~39 mL/min)，既往呋喹替尼致 AKI 史。</li>
<li><strong>Cardiovascular</strong>: 高血压 (硝苯地平)，心脏支架术后 (阿托伐他汀)。</li>
<li><strong>Metabolic</strong>: 糖尿病 (达格列净，阿卡波糖)。</li>
</ul>
<hr />
<h2>3. 分子特征 (Molecular Profile)</h2>
<h3>Actionable Alterations</h3>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Variant</th>
<th>Type</th>
<th>VAF</th>
<th>CIViC Level</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>KRAS</strong></td>
<td><strong>G12C</strong></td>
<td>SNV</td>
<td>11.5%</td>
<td>Level B</td>
<td><strong>FDA-approved (CRC combination)</strong><br>氟泽雷赛/Sotorasib/Adagrasib + Cetuximab 有效</td>
</tr>
<tr>
<td><strong>ATM</strong></td>
<td><strong>Germline</strong></td>
<td>Mutation</td>
<td>-</td>
<td>Level C</td>
<td><strong>Off-label / Trial</strong><br>提示铂类敏感 (已验证) 及 PARP 抑制剂潜在获益</td>
</tr>
</tbody>
</table>
<h3>Immune Biomarkers</h3>
<ul>
<li><strong>MSI Status</strong>: <strong>MSS</strong> (微卫星稳定) - pMMR (MLH1/PMS2/MSH2/MSH6 均阳性)</li>
<li><strong>TMB</strong>: <strong>79 mut/Mb</strong> (High ≥10) - <em>注: 尽管数值极高，但结合 MSS 及免疫治疗失败史，提示非免疫原性突变 (如 POLE 相关) 或冷肿瘤环境。</em></li>
<li><strong>PD-L1 TPS</strong>: CPS = 3 (低表达)</li>
</ul>
<h3>Co-Alterations</h3>
<ul>
<li><strong>EGFR</strong>: IHC 2+ (支持抗 EGFR 单抗结合 G12C 抑制剂使用)</li>
<li><strong>HER2</strong>: IHC 0 (阴性)</li>
<li><strong>NTRK</strong>: panTRF (-) (阴性)</li>
</ul>
<hr />
<h2>4. 治疗史回顾 (Treatment History)</h2>
<div class="treatment-timeline"><p>- line: 1线
  date: 2022.08-2022.12
  regimen: 奥沙利铂+卡培他滨+贝伐珠单抗 (5程)
  response: PR
  type: neoadjuvant
  note: 新辅助化疗，ATM突变可能贡献了铂类敏感性

- line: 手术
  date: 2023.01
  regimen: 根治性手术
  response: TRG2
  type: surgery
  note: 切除原发灶+肝转移+淋巴结清扫 (5/19阳性)

- line: 1线(辅助)
  date: 2023.03-2023.05
  regimen: 奥沙利铂+卡培他滨 (3程)
  response: -
  type: adjuvant
  note: 术后辅助化疗

- line: 1线(维持)
  date: 2023.05-2023.08
  regimen: 卡培他滨单药
  response: -
  type: maint
  note: 维持治疗，双肺出现小结节

- line: 2线
  date: 2023.08-2024.01
  regimen: 伊立替康+亚叶酸钙+5-FU+贝伐珠单抗 (FOLFIRI+Bev)
  response: SD
  type: pd
  note: 2023.8 CEA升高，双肺结节增大，判定进展

- line: 2线(维持)
  date: 2024.02-2024.06
  regimen: 卡培他滨单药
  response: -
  type: maint
  note: 维持治疗

- line: 3线
  date: 2024.07
  regimen: 呋喹替尼+信迪利单抗
  response: 毒性终止
  type: event
  note: 严重不良反应：急性肾损伤(AKI)+肢体水肿

- line: 3线(调整)
  date: 2024.09
  regimen: 雷替曲塞+信迪利单抗
  response: -
  type: event
  note: 出现发热(疑似感染)

- line: 3线(继续)
  date: 2024.10-2025.02
  regimen: 雷替曲塞+信迪利单抗
  response: SD(缩小)
  type: pd
  note: 病情暂时控制，CEA降至17.2；后进展

- line: 4线
  date: 2025.02-2025.10
  regimen: 信迪利单抗+抗肿瘤新抗原mRNA疫苗 (含KRAS G12C抗原)
  response: PD
  type: pd
  note: 肺转移增大，CEA升至112；副作用：发热，II度血小板减少

- line: 5线(当前)
  date: 2025.10-今
  regimen: 氟泽雷赛+西妥昔单抗
  response: 待评估
  type: current
  note: 针对KRAS G12C的精准靶向治疗</p></div>

<p><strong>Key Observations</strong>:<br />
- <strong>铂类敏感</strong>: 一线含铂方案获 PR，与 ATM 突变一致。<br />
- <strong>免疫耐药</strong>: 尽管 TMB 高，但信迪利单抗联合化疗、抗血管、疫苗均未能持久获益，确认为免疫难治。<br />
- <strong>肾毒性高危</strong>: 呋喹替尼曾致急性肾损伤，限制了后续 TKI (如瑞戈非尼) 的使用。</p>
<hr />
<h2>5. 药物/方案对比 (Regimen Comparison)</h2>
<p>针对当前及后续治疗的方案对比：</p>
<table>
<thead>
<tr>
<th>Regimen</th>
<th>Evidence Level</th>
<th>ORR</th>
<th>mPFS</th>
<th>Key Toxicities</th>
<th>Renal Safety</th>
<th>Access</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fulzerasib + Cetuximab</strong></td>
<td><strong>B</strong> (CodeBreaK 300同类)</td>
<td>~40%</td>
<td>6-8m</td>
<td>皮疹, 低镁血症</td>
<td>⚠️ 需监测镁</td>
<td>China Trial/Market</td>
</tr>
<tr>
<td><strong>TAS-102 + Bevacizumab</strong></td>
<td><strong>A</strong> (SUNLIGHT, NCCN Cat 1)</td>
<td>6.2%</td>
<td>5.6m</td>
<td>中性粒细胞减少</td>
<td>⚠️ 需减量</td>
<td>NMPA Approved</td>
</tr>
<tr>
<td><strong>Regorafenib</strong></td>
<td><strong>A</strong> (CORRECT)</td>
<td>1%</td>
<td>1.9m</td>
<td>手足皮肤反应, 肝肾毒性</td>
<td>❌ <strong>禁忌</strong></td>
<td>NMPA Approved</td>
</tr>
<tr>
<td><strong>PD-1 Inhibitors</strong></td>
<td><strong>D</strong> (In MSS CRC)</td>
<td>0%</td>
<td>2m</td>
<td>免疫性炎症</td>
<td>✓ Safe</td>
<td>NMPA Approved</td>
</tr>
</tbody>
</table>
<p><strong>Comparison Summary</strong>:<br />
氟泽雷赛联合西妥昔单抗是目前分子层面获益最大的方案。TAS-102 联合贝伐珠单抗是唯一证据充分且在调整剂量后对肾功能不全患者相对安全的后线选择。瑞戈非尼因高肾毒性风险及既往 AKI 史被排除。</p>
<hr />
<h2>6. 器官功能与剂量 (Organ Function &amp; Dosing)</h2>
<h3>Current Organ Function</h3>
<table>
<thead>
<tr>
<th>System</th>
<th>Parameter</th>
<th>Value</th>
<th>Normal Range</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Renal</strong></td>
<td><strong>eGFR</strong></td>
<td><strong>~39 mL/min</strong></td>
<td>&gt;90</td>
<td>⚠️ <strong>Impaired (Stage 3b)</strong></td>
</tr>
<tr>
<td>Renal</td>
<td>Creatinine</td>
<td>146 μmol/L</td>
<td>&lt;106</td>
<td>⚠️ Elevated</td>
</tr>
<tr>
<td>Hepatic</td>
<td>ALT/AST</td>
<td>Not listed</td>
<td>&lt;40</td>
<td>Assumed Stable</td>
</tr>
<tr>
<td>Hematologic</td>
<td>Platelets</td>
<td>History of Gr 2</td>
<td>&gt;100</td>
<td>⚠️ Monitor</td>
</tr>
<tr>
<td>Cardiac</td>
<td>Stent</td>
<td>Post-op</td>
<td>-</td>
<td>Stable</td>
</tr>
</tbody>
</table>
<h3>Dose Adjustments &amp; Safety</h3>
<p><strong>For Current Regimen (Fulzerasib + Cetuximab)</strong>:<br />
- <strong>Fulzerasib</strong>: 主要经肝代谢，通常无需根据肾功能调整，但需密切监测。<br />
- <strong>Cetuximab</strong>: <strong>每周监测血镁</strong>。低镁血症可加重肾小管损伤。<br />
- <strong>DDI 警报</strong>: 氟泽雷赛可能抑制 CYP3A4，需暂停或减量 <strong>阿托伐他汀</strong> (防横纹肌溶解伤肾) 及监测 <strong>硝苯地平</strong> (防低血压)。</p>
<p><strong>For Future Regimen (TAS-102)</strong>:<br />
- <strong>Renal Adjustment</strong>: eGFR 30-49 mL/min 时，剂量需从 35 mg/m² 减至 <strong>20 mg/m² BID</strong>。</p>
<hr />
<h2>7. 治疗路线图 (Treatment Roadmap)</h2>
<div class="card-grid">
            <div class="card" style="border-left: 4px solid var(--warning);">
              <div class="card-header">当前方案 (五线)</div>
              <p><strong>氟泽雷赛 (Fulzerasib) + 西妥昔单抗</strong></p>
              <ul><li>维持治疗，每6-8周CT评估</li><li>每日监测血压，每周查血镁/肌酐</li><li>暂停阿托伐他汀或换药</li></ul>
            </div>
            <div class="card" style="border-left: 4px solid var(--success);">
              <div class="card-header">若有效 (PR/SD)</div>
              <p><strong>持续维持</strong></p>
              <ul><li>直至疾病进展或毒性不可耐受</li><li>关注皮肤毒性管理</li></ul>
            </div>
            <div class="card" style="border-left: 4px solid var(--danger);">
              <div class="card-header">若进展 (PD)</div>
              <p><strong>TAS-102 + 贝伐珠单抗 (肾功能减量版)</strong></p>
              <ul><li>剂量调整为 20mg/m²</li><li>优先考虑 NCT06293014 试验</li><li>液体活检寻找耐药机制</li></ul>
            </div></div>

<hr />
<h2>8. 分子复查建议 (Re-biopsy / Liquid Biopsy)</h2>
<p><strong>Timing</strong>: 在当前靶向治疗 (氟泽雷赛+西妥昔单抗) 进展时。</p>
<p><strong>Purpose</strong>:<br />
- 探测 <strong>KRAS G12C 获得性耐药突变</strong> (如 Y96D, G12D/V)。<br />
- 探测 <strong>MET 扩增</strong> (常见的旁路激活机制)。<br />
- 探测 <strong>EGFR 胞外域突变</strong> (导致西妥昔单抗失效)。</p>
<p><strong>Method</strong>: <strong>液体活检 (ctDNA)</strong>。<br />
- <em>理由</em>: 患者肺部多发转移，且肾功能差不宜频繁穿刺或使用造影剂，血液检测最为安全可行。</p>
<hr />
<h2>9. 临床试验推荐 (Clinical Trials)</h2>
<p>以下试验由 Recruiter 筛选，已根据患者肾功能 (eGFR ~39) 进行优先级排序。</p>
<h3>Top Recommended Trials (China Sites)</h3>
<h4>Trial 1: <a href="https://clinicaltrials.gov/study/NCT06293014" class="reference" target="_blank">[NCT06293014]</a> - TAS-102联合贝伐珠单抗治疗</h4>
<p><strong>Phase</strong>: II<br />
<strong>Drug</strong>: TAS-102 (Trifluridine/Tipiracil) + Bevacizumab<br />
<strong>Target</strong>: 化疗/抗血管耐药<br />
<strong>Status</strong>: 招募中<br />
<strong>Sites</strong>: 河南肿瘤医院 (郑州) 等<br />
<strong>Eligibility</strong>: 晚期结直肠癌，既往标准治疗失败。<br />
<strong>Rationale</strong>: SUNLIGHT 研究证实该组合优于单药。TAS-102 说明书允许在肾功能不全患者中减量使用，是目前最适合该患者的试验方案。<br />
<strong>Reference</strong>: <a href="https://clinicaltrials.gov/study/NCT06293014">NCT06293014</a></p>
<h4>Trial 2: <a href="https://clinicaltrials.gov/study/NCT05489211" class="reference" target="_blank">[NCT05489211]</a> - Dato-DXd (TROP2 ADC) 实体瘤篮子试验</h4>
<p><strong>Phase</strong>: II<br />
<strong>Drug</strong>: Datopotamab Deruxtecan<br />
<strong>Target</strong>: TROP2<br />
<strong>Status</strong>: 招募中<br />
<strong>Sites</strong>: 广州、长沙、重庆、杭州多中心<br />
<strong>Eligibility</strong>: 晚期实体瘤，标准治疗进展。<br />
<strong>Rationale</strong>: TROP2 在肠癌高表达。ADC 药物可能克服靶向耐药。<br />
<strong>Warning</strong>: <strong>需严格核实肾功能入组门槛</strong> (通常要求 CrCl &gt;30 或 &gt;50)。</p>
<h4>Trial 3: [Basket Trial] - PARP 抑制剂探索性治疗</h4>
<p><strong>Phase</strong>: I/II<br />
<strong>Drug</strong>: Fluzoparib / Pamiparib<br />
<strong>Target</strong>: ATM / DDR Pathway<br />
<strong>Status</strong>: 需咨询 I 期病房 (如中山肿瘤、北肿)<br />
<strong>Rationale</strong>: 患者携带 <strong>ATM 胚系突变</strong>，理论上存在合成致死效应。<br />
<strong>Warning</strong>: PARP 抑制剂主要经肾排泄，需极谨慎评估剂量。</p>
<h3>Backup Trials</h3>
<ul>
<li><strong>NCT04793958 (CodeBreaK 300)</strong>: 若仍有扩展队列，可考虑 Sotorasib + Panitumumab (同类药参考)。</li>
</ul>
<hr />
<h2>10. 局部治疗建议 (Local Therapy)</h2>
<p><strong>Indications</strong>:<br />
- <strong>Oligoprogression (寡进展)</strong>: 若全身病灶控制良好，仅 1-2 个肺结节增大。<br />
- <strong>Symptomatic</strong>: 气道压迫或咯血。</p>
<p><strong>Current Patient</strong>:<br />
- 目前双肺多发转移，处于全身系统性进展期，暂不适合局部消融或手术。<br />
- 若当前靶向治疗有效，残留个别活性病灶时，可考虑 <strong>SBRT (立体定向放疗)</strong>，但需注意肺部毒性。</p>
<hr />
<h2>11. 核心建议汇总 (Core Recommendations)</h2>
<h3>Recommended Treatment Plan</h3>
<ol>
<li>
<p><strong>Immediate (当前)</strong>: <strong>氟泽雷赛 + 西妥昔单抗</strong> - <strong><span class="evidence-tag evidence-b">Evidence B</span></strong></p>
<ul>
<li><strong>Rationale</strong>: 针对 KRAS G12C/EGFR 通路的双重阻断，是目前生物学证据最强的方案。</li>
<li><strong>Safety</strong>: 每周查血镁，关注皮疹。暂停阿托伐他汀。</li>
</ul>
</li>
<li>
<p><strong>Next Line (后线)</strong>: <strong>TAS-102 (减量) + 贝伐珠单抗</strong> - <strong><span class="evidence-tag evidence-a">Evidence A</span></strong></p>
<ul>
<li><strong>Rationale</strong>: SUNLIGHT 研究证实生存获益。</li>
<li><strong>Dosing</strong>: 必须调整为 <strong>20 mg/m² BID</strong> 以适应 eGFR 39 mL/min 的肾功能。</li>
</ul>
</li>
<li>
<p><strong>Monitoring</strong>:</p>
<ul>
<li>Labs: 每周查肾功能、电解质 (Mg/K)、血常规。</li>
<li>Imaging: 每 6-8 周 CT 平扫 (避免造影剂)。</li>
</ul>
</li>
</ol>
<h3>Not Recommended (Critical!)</h3>
<p><strong>DO NOT USE</strong>:<br />
1.  <strong>❌ 瑞戈非尼 (Regorafenib)</strong>: 既往呋喹替尼致 AKI，再挑战多激酶抑制剂极高风险导致肾衰竭 <strong>[Safety Contraindication]</strong>。<br />
2.  <strong>❌ 顺铂 (Cisplatin) / 高剂量 NSAIDs</strong>: 绝对禁忌，因肾毒性。<br />
3.  <strong>❌ PD-1 单药</strong>: 患者为 MSS 且既往免疫联合治疗多线失败，单药无效 <strong>[Evidence A - Negative]</strong>。</p>
<h3>Palliative Care</h3>
<ul>
<li>建议肾内科随诊，管理慢性肾病。</li>
<li>建议直系亲属进行 <strong>ATM 基因</strong> 遗传咨询。</li>
</ul>
<hr />
<h2>12. 参考文献 (References)</h2>
<ol>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/37870968/">PMID: 37870968 - CodeBreaK 300: Sotorasib plus Panitumumab in KRAS G12C CRC</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/37141369/">PMID: 37141369 - SUNLIGHT: Trifluridine-Tipiracil and Bevacizumab</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/40715048/">PMID: 40715048 - Fulzerasib (IBI351) Phase I/II Data</a></li>
<li><a href="https://clinicaltrials.gov/study/NCT06293014">NCT06293014 - TAS-102 plus Bevacizumab Trial</a></li>
<li><a href="https://www.nccn.org/guidelines">NCCN Guidelines for Colon Cancer v1.2025</a></li>
<li><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207981s008lbl.pdf">FDA Label - LONSURF (TAS-102) Dosing in Renal Impairment</a></li>
</ol>

      
      <div class="warning-box">
        <strong>⚠️ 安全警告</strong>
        <ul>
        
          <li>| **Fulzerasib + Cetuximab** | **B** (CodeBreaK 300同类) | ~40% | 6-8m | 皮疹, 低镁血症 | ⚠️ 需监测镁 | China Trial/Market |</li>
        
          <li>| **TAS-102 + Bevacizumab** | **A** (SUNLIGHT, NCCN Cat 1) | 6.2% | 5.6m | 中性粒细胞减少 | ⚠️ 需减量 | NMPA Approved |</li>
        
          <li>| **Regorafenib** | **A** (CORRECT) | 1% | 1.9m | 手足皮肤反应, 肝肾毒性 | ❌ **禁忌** | NMPA Approved |</li>
        
          <li>| **Renal** | **eGFR** | **~39 mL/min** | &gt;90 | ⚠️ **Impaired (Stage 3b)** |</li>
        
          <li>| Renal | Creatinine | 146 μmol/L | &lt;106 | ⚠️ Elevated |</li>
        
        </ul>
      </div>
      

      
      <h2>参考文献</h2>
      <ol>
      
        <li>
          <a href="https://clinicaltrials.gov/study/NCT06293014" class="reference" target="_blank">
            [NCT: NCT06293014]
          </a>
        </li>
      
      </ol>
      
    </div>

    <footer>
      <p><strong>免责声明:</strong> 本报告仅供临床参考。具体治疗决策应由主治医师根据患者实际情况和最新临床证据综合判断。</p>
      <p>虚拟分子肿瘤委员会会诊报告 | 生成日期: 2026-01-19 19:36:11</p>
    </footer>

  </div>
</body>
</html>